OmniAb (OABI) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.12
- Estimate
- -$0.13
- Surprise
- +7.7%
- Revenue (period 2026-09-30)
- $4.0M
- Score at report (before → after)
- 5.3 → 5.5/10
Revenue source: xbrl.
How the report landed
OmniAb (OABI) reported a narrower loss than forecast — adjusted EPS of -$0.12 against the -$0.13 estimate (a 7.7% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Hold at 5.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates OABI Hold at 6.2/10.
3 of the last 4 quarters beat the estimate; this quarter's +7.7% surprise compares with a +20.2% four-quarter average. Next scheduled report: 2027-03-04.
What supports the rating
- Sector modifier (Healthcare): +0.8
- Strong earnings beat streak (3/4)
What argues against it
- Elevated risk factors
- Momentum score 4.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.66
- Price target
- $7.25
- Stop
- $4.33
- Upside to target
- +55.6%
- Reward-to-risk
- 4.0:1
Model outputs from TrendMatrix’s engine as of 2026-11-20 — shown for context, not personalized investment advice.
OABI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $733.7M
- P/E (fwd)
- -19.3
- 52-week range
- $1.35–$5.45
- Off 52-week high
- 14.5%
- RSI (14)
- 39
- Volume vs avg
- 1.28×
- Score today
- 6.2/10